EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Novel molecular mechanism driving neuroprotection after soluble epoxide hydrolase inhibition: Insights for Alzheimer's disease therapeutics

Christian Griñán-Ferré, Júlia Jarné-Ferrer, Aina Bellver-Sanchís, Sandra Codony, Dolors Puigoriol-Illamola, Coral Sanfeliu, Yumin Oh, Seulki Lee, Santiago Vázquez, Mercè Pallàs iD

CNS Neuroscience & Therapeutics · 2024

DOI: 10.1111/cns.14511 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2024. Verfasst von Christian Griñán-Ferré und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Therapeutic Chemistry, Institut de Neurociències-Universitat de Barcelona, Barcelona, Spain. Hauptthemen laut MEDLINE: Alzheimer Disease, Epoxide Hydrolases. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agència de Gestió d'Ajuts Universitaris i de Recerca, Ministerio de Ciencia e Innovación, Spanish Ministerio de Ciencia e Innovación.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Neuroinflammation is widely recognized as a significant hallmark of Alzheimer's disease (AD). To combat neuroinflammation, the inhibition of the soluble epoxide hydrolase (sEH) enzyme has been demonstrated crucial. Importantly, sEH inhibition could be related to other neuroprotective pathways described in AD.

Aims

The aim of the study was to unveil new molecular pathways driving neuroprotection through sEH, we used an optimized, potent, and selective sEH inhibitor (sEHi, UB‐SCG‐51). Materials and Methods UB‐SCG‐51 was tested in neuroblastoma cell line, SH‐SY5Y, in primary mouse and human astrocytes cultures challenged with proinflammatory insults and in microglia cultures treated with amyloid oligomers, as well as in mice AD model (5XFAD).

Results

UB‐SCG‐51 (10 and 30 μM) prevented neurotoxic reactive‐astrocyte conversion in primary mouse astrocytes challenged with TNF‐α, IL‐1α, and C1q (T/I/C) combination for 24 h. Moreover, in microglial cultures, sEHi reduced inflammation and glial activity. In addition, UB‐SCG‐51 rescued 5XFAD cognitive impairment, reducing the number of Amyloid‐β plaques and Tau hyperphosphorylation accompanied by a reduction in neuroinflammation and apoptotic markers. Notably, a transcriptional profile analysis revealed a new pathway modulated by sEHi treatment. Specifically, the eIF2α/CHOP pathway, which promoted the endoplasmic reticulum response, was increased in the 5XFAD‐treated group. These findings were confirmed in human primary astrocytes by combining sEHi and eIF2α inhibitor (eIF2αi) treatment. Besides, combining both treatments resulted in increased in C3 gene expression after T/I/C compared with the group treated with sEHi alone in cultures.

Discussion

Therefore, sEHi rescued cognitive impairment and neurodegeneration in AD mice model, based on the reduction of inflammation and eIF2α/CHOP signaling pathway.

Conclusions

In whole, our results support the concept that targeting neuroinflammation through sEH inhibition is a promising therapeutic strategy to fight against Alzheimer's disease with additive and/or synergistic activities targeting neuroinflammation and cell stress.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseEpoxide HydrolasesAnimalsHumansMiceAmyloid beta-PeptidesDisease Models, AnimalInflammationMice, TransgenicNeuroblastomaNeuroinflammatory DiseasesNeuroprotectionCell Line, Tumor

Stichwörter der Autor:innen

5XFADendoplasmic reticulum stressepoxide hydrolaseglianeuroinflammation

Substanzen

Amyloid beta-PeptidesEpoxide Hydrolases

Autor:innen und Institutionen

  • Department of Pharmacology and Therapeutic Chemistry, Institut de Neurociències-Universitat de Barcelona, Barcelona, Spain.
  • Centro de Investigación en Red, Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.
  • Laboratory of Medicinal Chemistry (CSIC Associated Unit), Faculty of Pharmacy and Food Sciences, Institute of Biomedicine (IBUB), University of Barcelona (UB), Barcelona, Spain.
  • Institut d'Investigacions Biomèdiques de Barcelona (IIBB), Consejo Superior de Investigaciones Científicas (CSIC), Barcelona, Spain.
  • Neuraly Inc., Maryland, Gaithersburg, USA.

ORCID-Profile: Mercè Pallàs

Förderung

  • Agència de Gestió d'Ajuts Universitaris i de Recerca
  • Ministerio de Ciencia e Innovación
  • Spanish Ministerio de Ciencia e Innovación
  • María de Maeztu Unit of Excellence to Institute of Neurosciences
  • AGAUR Catalonia

Zitieren

APA

Griñán-Ferré, C., Jarné-Ferrer, J., Bellver-Sanchís, A., Codony, S., Puigoriol-Illamola, D., Sanfeliu, C., Oh, Y., Lee, S., Vázquez, S., & Pallàs, M. (2024). Novel molecular mechanism driving neuroprotection after soluble epoxide hydrolase inhibition: Insights for Alzheimer's disease therapeutics. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.14511

Vancouver

Griñán-Ferré C, Jarné-Ferrer J, Bellver-Sanchís A, Codony S, Puigoriol-Illamola D, Sanfeliu C, et al. Novel molecular mechanism driving neuroprotection after soluble epoxide hydrolase inhibition: Insights for Alzheimer's disease therapeutics. CNS Neuroscience & Therapeutics. 2024. doi:10.1111/cns.14511

BibTeX
@article{GrinFerr2024,
  author = {Griñán-Ferré, Christian and Jarné-Ferrer, Júlia and Bellver-Sanchís, Aina and Codony, Sandra and Puigoriol-Illamola, Dolors and Sanfeliu, Coral and Oh, Yumin and Lee, Seulki and Vázquez, Santiago and Pallàs, Mercè},
  title = {Novel molecular mechanism driving neuroprotection after soluble epoxide hydrolase inhibition: Insights for Alzheimer's disease therapeutics},
  journal = {CNS Neuroscience & Therapeutics},
  year = {2024},
  doi = {10.1111/cns.14511}
}
Kostenlos starten →